| Dr William J Mcfeely Jr, MD | |
|
1963 Memorial Parkway Sw, Suite 5, Huntsville, AL 35801 | |
| (256) 536-9300 | |
| (256) 535-9032 |
| Full Name | Dr William J Mcfeely Jr |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 32 Years |
| Location | 1963 Memorial Parkway Sw, Huntsville, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962593442 | NPI | - | NPPES |
| 174148900 | Other | US DEPARTMENT OF LABOR | |
| 0007915022 | Other | AETNA | |
| 040016076 | Other | RAILROAD RETIREMENT | |
| 009952050 | Medicaid | AL | |
| 51501958 | Other | AL | BLUECROSS BLUESHIELD |
| 51501685 | Other | AL | BLUECROSS BLUESHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 00022355 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Huntsville Hospital | Huntsville, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Alabama Ent Associates | 5597744748 | 24 |
News Archive
A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.
BioGenes GmbH, a supplier of GMP-compliant immunoassays and antibodies, completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein assay. The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.
Researchers at the Buck Institute for Age Research have successfully used human induced pluripotent stem cells (iPSCs) to treat rodents afflicted with Parkinson's Disease (PD). The research, which validates a scalable protocol that the same group had previously developed, can be used to manufacture the type of neurons needed to treat the disease and paves the way for the use of iPSC's in various biomedical applications. Results of the research, from the laboratory of Buck faculty Xianmin Zeng, Ph.D., are published August 16, 2010 in the on-line edition of the journal Stem Cells.
The Med-Tech Innovation Expo 2019 brings together the most exciting speakers, products, and innovations in MedTech, medical plastics, digital devices, and pharmaceuticals.
› Verified 5 days ago
| Entity Name | North Alabama Ent Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437279601 PECOS PAC ID: 5597744748 Enrollment ID: O20040720000529 |
News Archive
A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.
BioGenes GmbH, a supplier of GMP-compliant immunoassays and antibodies, completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein assay. The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.
Researchers at the Buck Institute for Age Research have successfully used human induced pluripotent stem cells (iPSCs) to treat rodents afflicted with Parkinson's Disease (PD). The research, which validates a scalable protocol that the same group had previously developed, can be used to manufacture the type of neurons needed to treat the disease and paves the way for the use of iPSC's in various biomedical applications. Results of the research, from the laboratory of Buck faculty Xianmin Zeng, Ph.D., are published August 16, 2010 in the on-line edition of the journal Stem Cells.
The Med-Tech Innovation Expo 2019 brings together the most exciting speakers, products, and innovations in MedTech, medical plastics, digital devices, and pharmaceuticals.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William J Mcfeely Jr, MD Po Box 18066, Huntsville, AL 35804-8066 Ph: (256) 536-9300 | Dr William J Mcfeely Jr, MD 1963 Memorial Parkway Sw, Suite 5, Huntsville, AL 35801 Ph: (256) 536-9300 |
News Archive
A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.
BioGenes GmbH, a supplier of GMP-compliant immunoassays and antibodies, completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein assay. The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.
Researchers at the Buck Institute for Age Research have successfully used human induced pluripotent stem cells (iPSCs) to treat rodents afflicted with Parkinson's Disease (PD). The research, which validates a scalable protocol that the same group had previously developed, can be used to manufacture the type of neurons needed to treat the disease and paves the way for the use of iPSC's in various biomedical applications. Results of the research, from the laboratory of Buck faculty Xianmin Zeng, Ph.D., are published August 16, 2010 in the on-line edition of the journal Stem Cells.
The Med-Tech Innovation Expo 2019 brings together the most exciting speakers, products, and innovations in MedTech, medical plastics, digital devices, and pharmaceuticals.
› Verified 5 days ago
Dr. Joseph Stephen Brigance, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 201 Whitesport Drive, Huntsville, AL 35801 Phone: 256-881-5353 Fax: 256-881-0712 | |
Sundeep Alapati, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 927 Franklin St Se Ste 100, Huntsville, AL 35801 Phone: 256-536-9300 Fax: 256-535-9032 | |
Dr. Michael D Mcfadden, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1963 Memorial Parkway Sw, Suite 5, Huntsville, AL 35801 Phone: 256-536-9300 Fax: 256-535-9032 | |
Benjamin David Powell, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 201 Whitesport Dr Sw, Huntsville, AL 35801 Phone: 256-881-5353 Fax: 256-881-0712 | |
Dr. Neeta Kohli-dang, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 285 Chateau Dr, Huntsville, AL 35801 Phone: 256-882-0165 Fax: 256-882-7846 | |
Dr. Herman Mckinley Teachey, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1963 Memorial Parkway Sw, Suite 5, Huntsville, AL 35801 Phone: 256-536-9300 Fax: 256-535-9032 | |
Dr. Jason P Lockette, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 8 Ross St Nw, Huntsville, AL 35806 Phone: 256-366-0899 |